- Home
- HNRG vs NRIX Comparison
HNRG vs NRIX Comparison
Compare HNRG & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HNRG
- NRIX
- Stock Information
- Founded
- HNRG 1949
- NRIX 2009
- Country
- HNRG United States
- NRIX United States
- Employees
- HNRG N/A
- NRIX N/A
- Industry
- HNRG Coal Mining
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- HNRG Energy
- NRIX Health Care
- Exchange
- HNRG Nasdaq
- NRIX Nasdaq
- Market Cap
- HNRG 912.0M
- NRIX 766.0M
- IPO Year
- HNRG N/A
- NRIX 2020
- Fundamental
- Price
- HNRG $17.16
- NRIX $10.56
- Analyst Decision
- HNRG Buy
- NRIX Strong Buy
- Analyst Count
- HNRG 3
- NRIX 15
- Target Price
- HNRG $19.00
- NRIX $29.13
- AVG Volume (30 Days)
- HNRG 850.8K
- NRIX 678.5K
- Earning Date
- HNRG 08-11-2025
- NRIX 10-10-2025
- Dividend Yield
- HNRG N/A
- NRIX N/A
- EPS Growth
- HNRG N/A
- NRIX N/A
- EPS
- HNRG N/A
- NRIX N/A
- Revenue
- HNRG $419,451,000.00
- NRIX $88,381,000.00
- Revenue This Year
- HNRG N/A
- NRIX $71.51
- Revenue Next Year
- HNRG $9.86
- NRIX N/A
- P/E Ratio
- HNRG N/A
- NRIX N/A
- Revenue Growth
- HNRG N/A
- NRIX 41.86
- 52 Week Low
- HNRG $5.58
- NRIX $8.18
- 52 Week High
- HNRG $22.01
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- HNRG 48.15
- NRIX 43.38
- Support Level
- HNRG $16.32
- NRIX $9.44
- Resistance Level
- HNRG $22.01
- NRIX $10.98
- Average True Range (ATR)
- HNRG 1.37
- NRIX 0.57
- MACD
- HNRG -0.04
- NRIX -0.08
- Stochastic Oscillator
- HNRG 23.14
- NRIX 38.75
About HNRG Hallador Energy Company
Hallador Energy Co is a coal mining company with operations in Indiana, USA, and it is part of the electric power generation industry. The operations of the company are divided into two primary reportable segments, the Coal Operations and Electric Operations segments. The majority of revenue is earned from the Coal Operations segment.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.